TG Therapeutics Inc (NASDAQ:TGTX) – SunTrust Banks decreased their FY2018 earnings per share estimates for TG Therapeutics in a report released on Wednesday, November 28th. SunTrust Banks analyst P. Lawson now expects that the biopharmaceutical company will post earnings of ($2.06) per share for the year, down from their prior estimate of ($2.02). SunTrust Banks also issued estimates for TG Therapeutics’ FY2019 earnings at ($2.06) EPS, FY2020 earnings at ($2.66) EPS and FY2021 earnings at ($1.91) EPS.
TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Friday, November 9th. The biopharmaceutical company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.12. TG Therapeutics had a negative net margin of 99,001.33% and a negative return on equity of 185.20%. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million.
A number of other equities analysts have also commented on the stock. Raymond James lowered shares of TG Therapeutics from a “strong-buy” rating to an “outperform” rating and cut their price objective for the stock from $22.00 to $12.00 in a report on Tuesday, September 25th. HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of TG Therapeutics in a report on Tuesday, August 7th. LADENBURG THALM/SH SH set a $27.00 price objective on shares of TG Therapeutics and gave the stock a “buy” rating in a report on Wednesday, September 26th. ValuEngine lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, September 26th. Finally, Zacks Investment Research upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a report on Friday, November 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $18.35.
Shares of TGTX stock opened at $5.04 on Monday. TG Therapeutics has a 12 month low of $4.20 and a 12 month high of $17.35. The firm has a market capitalization of $417.80 million, a price-to-earnings ratio of -2.64 and a beta of 1.77.
A number of hedge funds have recently modified their holdings of TGTX. Highland Capital Management LP increased its position in shares of TG Therapeutics by 1.0% in the 2nd quarter. Highland Capital Management LP now owns 469,241 shares of the biopharmaceutical company’s stock worth $6,171,000 after purchasing an additional 4,850 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of TG Therapeutics by 3.7% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 144,236 shares of the biopharmaceutical company’s stock worth $1,897,000 after purchasing an additional 5,165 shares during the last quarter. MetLife Investment Advisors LLC increased its position in shares of TG Therapeutics by 35.2% in the 2nd quarter. MetLife Investment Advisors LLC now owns 28,284 shares of the biopharmaceutical company’s stock worth $372,000 after purchasing an additional 7,358 shares during the last quarter. Rhumbline Advisers increased its position in shares of TG Therapeutics by 18.3% in the 2nd quarter. Rhumbline Advisers now owns 54,587 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 8,435 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of TG Therapeutics by 3.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 286,843 shares of the biopharmaceutical company’s stock worth $1,606,000 after purchasing an additional 10,518 shares during the last quarter. Hedge funds and other institutional investors own 49.76% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.